AcquisitionsJul 8, 2026, 04:18 PM
Galmed Acquires Colospan for $3.3M Cash; Q1 Net Loss $1.91M
AI Summary
Galmed Pharmaceuticals completed the acquisition of Colospan Ltd. on June 22, 2026, for $3.3 million in cash and up to $2.0 million in performance-based earnout consideration. For the first quarter of 2026, the company reported a net loss of $1.91 million, an increase from $1.10 million in the same period last year, primarily due to higher research and development expenses. Galmed continues to pursue opportunities to expand its product pipeline, particularly in cardiometabolic indications.
Key Highlights
- Acquired Colospan Ltd. on June 22, 2026, making it a wholly-owned subsidiary.
- Paid $3.3 million in cash and up to $2.0 million in performance-based earnout for Colospan.
- Reported a net loss of $1.91 million for Q1 2026, compared to $1.10 million in Q1 2025.
- Research and development expenses increased to $1.36 million in Q1 2026 from $0.63 million in Q1 2025.
- Cash and cash equivalents stood at $1.60 million as of March 31, 2026.
- Total current assets decreased to $16.03 million as of March 31, 2026, from $18.63 million at year-end 2025.
- Subsequent to Q1 2026, sold 1,361,000 ordinary shares for $1.2 million via SEPA.
Price Impact
More from GLMD